EP1202737A4 - Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral - Google Patents

Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral

Info

Publication number
EP1202737A4
EP1202737A4 EP00967364A EP00967364A EP1202737A4 EP 1202737 A4 EP1202737 A4 EP 1202737A4 EP 00967364 A EP00967364 A EP 00967364A EP 00967364 A EP00967364 A EP 00967364A EP 1202737 A4 EP1202737 A4 EP 1202737A4
Authority
EP
European Patent Office
Prior art keywords
antiviral therapy
therapy use
glycoprotein modulators
glycoprotein
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00967364A
Other languages
German (de)
English (en)
Other versions
EP1202737A2 (fr
Inventor
Alastair J J Wood
Richard B Kim
Grant R Wilkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of EP1202737A2 publication Critical patent/EP1202737A2/fr
Publication of EP1202737A4 publication Critical patent/EP1202737A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP00967364A 1999-08-09 2000-08-07 Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral Withdrawn EP1202737A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37026699A 1999-08-09 1999-08-09
US370266 1999-08-09
PCT/US2000/040588 WO2001010387A2 (fr) 1999-08-09 2000-08-07 Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral

Publications (2)

Publication Number Publication Date
EP1202737A2 EP1202737A2 (fr) 2002-05-08
EP1202737A4 true EP1202737A4 (fr) 2005-03-02

Family

ID=23458912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00967364A Withdrawn EP1202737A4 (fr) 1999-08-09 2000-08-07 Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral

Country Status (5)

Country Link
EP (1) EP1202737A4 (fr)
JP (1) JP2003523944A (fr)
AU (1) AU7757400A (fr)
CA (1) CA2378984A1 (fr)
WO (1) WO2001010387A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6398199B1 (en) 1999-09-03 2002-06-04 Barber Manufacturing Company, Inc. Coil spring assembly
CA2401749A1 (fr) 2000-03-23 2001-09-27 Elan Pharmaceuticals, Inc. Composes et methodes de traitement de la maladie d'alzheimer
BR0210122A (pt) 2001-06-01 2004-06-15 Elan Pharm Inc Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
WO2002100818A2 (fr) 2001-06-13 2002-12-19 Elan Pharmaceuticals, Inc. Aminediols pour le traitement de la maladie d'alzheimer
CA2453444A1 (fr) 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Diaminediols pour le traitement de la maladie d'alzheimer
US7053109B2 (en) 2001-07-10 2006-05-30 Pharmacia & Upjohn Company Aminediols for the treatment of Alzheimer's disease
EP1432674A2 (fr) 2001-10-04 2004-06-30 Elan Pharmaceuticals, Inc. Hydroxypropylamines
JP2005520791A (ja) 2001-11-08 2005-07-14 イーラン ファーマスーティカルズ、インコーポレイテッド Ｎ，ｎ’−置換−１，３−ジアミノ−２−ヒドロキシプロパン誘導体
EP1453788A1 (fr) 2001-12-06 2004-09-08 Elan Pharmaceuticals, Inc. Hydroxyethylamines substitues
WO2004058686A1 (fr) 2002-04-30 2004-07-15 Elan Pharmaceuticals, Inc. Amides hydroxypropyle pour le traitement de la maladie d'alzheimer
JP2006524255A (ja) 2003-04-21 2006-10-26 イーラン ファーマスーティカルズ、インコーポレイテッド ベンズアミド２−ヒドロキシ−３−ジアミノアルカン
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007533740A (ja) 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー Ｂａｃｅ阻害剤としてのアミド
US7385085B2 (en) 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
WO2007047305A1 (fr) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Procedes de traitement de l'amyloïdose en utilisant des derives de cyclopropyle inhibiteurs de l'aspartyle-protease
JP2011231127A (ja) * 2011-08-01 2011-11-17 Sekisui Medical Co Ltd 経口吸収改善剤およびこれを利用する医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5939456A (en) * 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO0110387A3 *

Also Published As

Publication number Publication date
WO2001010387A2 (fr) 2001-02-15
CA2378984A1 (fr) 2001-02-15
AU7757400A (en) 2001-03-05
JP2003523944A (ja) 2003-08-12
WO2001010387A3 (fr) 2001-08-23
EP1202737A2 (fr) 2002-05-08

Similar Documents

Publication Publication Date Title
GB9911863D0 (en) Therapeutic agents
GB9905010D0 (en) Therapeutic agents
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
EP1202737A4 (fr) Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral
GB9911881D0 (en) Therapeutic agents
IL130171A0 (en) Therapeutic use of melatonin
GB9903476D0 (en) Therapeutic agents
GB9903119D0 (en) Therapeutic agents
GB9723999D0 (en) Therapeutic use
PL350963A1 (en) Use of arylalkanoylpyridazines
GB9902881D0 (en) Therapeutic agents
GB9914743D0 (en) Therapeutic agents
GB9911238D0 (en) Therapeutic use
GB9903919D0 (en) Aminophenols and their therapeutic use
AU2595201A (en) Antiviral therapeutic composition and treatment
GB9901904D0 (en) RTherapeutic use of human pheramones
IL133342A0 (en) Electrostatic stimulation of the human body
GB9726702D0 (en) Therapeutic use
GB9921953D0 (en) Therapeutic use
GB9912184D0 (en) Therapeutic use
GB9913350D0 (en) Therapeutic use
GB9721173D0 (en) Therapeutic use
GB9721171D0 (en) Therapeutic use
GB9721195D0 (en) Therapeutic use
GB9721220D0 (en) Therapeutic use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020214

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

A4 Supplementary search report drawn up and despatched

Effective date: 20050117

18W Application withdrawn

Effective date: 20050218